[go: up one dir, main page]

AU2001248971A1 - Use of npy y1 receptor agonists in the treatment of pain conditions - Google Patents

Use of npy y1 receptor agonists in the treatment of pain conditions

Info

Publication number
AU2001248971A1
AU2001248971A1 AU2001248971A AU4897101A AU2001248971A1 AU 2001248971 A1 AU2001248971 A1 AU 2001248971A1 AU 2001248971 A AU2001248971 A AU 2001248971A AU 4897101 A AU4897101 A AU 4897101A AU 2001248971 A1 AU2001248971 A1 AU 2001248971A1
Authority
AU
Australia
Prior art keywords
npy
treatment
receptor agonists
pain conditions
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248971A
Inventor
Guilherme De Araujo Lucas
Patrik Ernfors
Hassameh Hassani
Philippe Naveilhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of AU2001248971A1 publication Critical patent/AU2001248971A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001248971A 2000-04-13 2001-04-12 Use of npy y1 receptor agonists in the treatment of pain conditions Abandoned AU2001248971A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001373A SE0001373D0 (en) 2000-04-13 2000-04-13 NPY Y1 receptor agonists and antagonists
SE0001373 2000-04-13
PCT/SE2001/000827 WO2001078762A1 (en) 2000-04-13 2001-04-12 Use of npy y1 receptor agonists in the treatment of pain conditions

Publications (1)

Publication Number Publication Date
AU2001248971A1 true AU2001248971A1 (en) 2001-10-30

Family

ID=20279307

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001248971A Abandoned AU2001248971A1 (en) 2000-04-13 2001-04-12 Use of npy y1 receptor agonists in the treatment of pain conditions
AU2001248972A Abandoned AU2001248972A1 (en) 2000-04-13 2001-04-12 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001248972A Abandoned AU2001248972A1 (en) 2000-04-13 2001-04-12 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions

Country Status (6)

Country Link
US (1) US20030153487A1 (en)
EP (1) EP1276498A1 (en)
AU (2) AU2001248971A1 (en)
CA (1) CA2405600A1 (en)
SE (1) SE0001373D0 (en)
WO (2) WO2001078763A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (en) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh NEW USE OF A CLASS OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF NON-NEUROPATHIC INFLAMMATORY PAIN
DK1243263T3 (en) 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hitherto unknown use of a class of peptide compounds to treat allodynia or other various types of chronic or phantom pain
EP1689378B1 (en) 2003-12-02 2009-04-15 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
CN1950101B (en) 2004-04-16 2011-03-30 舒沃茨药物股份公司 Use of peptidic compounds for the prophylaxis and treatment of chronic headache
WO2005114213A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1)
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
KR20070045271A (en) 2004-08-27 2007-05-02 쉬바르츠파르마에이지 Use of peptide compounds for treatment of bone cancer pain, chemotherapy- and nucleoside-induced pain
EP2992891B1 (en) 2006-06-15 2020-08-05 UCB Pharma GmbH Pharmaceutical composition comprising brivaracetam and lacosamide with synergistic anticonvulsant effect

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569742A (en) * 1994-06-22 1996-10-29 The Salk Institute For Biological Studies Centrally truncated NPY cyclic peptides

Also Published As

Publication number Publication date
AU2001248972A1 (en) 2001-10-30
WO2001078762A1 (en) 2001-10-25
SE0001373D0 (en) 2000-04-13
WO2001078763A1 (en) 2001-10-25
US20030153487A1 (en) 2003-08-14
CA2405600A1 (en) 2001-10-25
EP1276498A1 (en) 2003-01-22

Similar Documents

Publication Publication Date Title
PT1757606E (en) Xanthinderivatives for use as medical agents and the preparation thereof
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
GB0121774D0 (en) Medical device and use therof
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
GB9904252D0 (en) Composition for the treatment of pain
ZA200205415B (en) Novel therapeutic use of enoxaparin.
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
AU2001233934A1 (en) Ccr2-64i, polymorphic variant of the human ccrs receptor and its use in the diagnostic and treatment of atherosclerosis
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002334251A1 (en) Mifaxin agonists and antagonists for use in the treatment of metabolic
AU2002339674A1 (en) Ditacin agonists and antagonists for use in the treatment of metabolic disorders
AU2002324288A1 (en) Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
AU2002328172A1 (en) Agonists and antagonists of modumet for use in the treatment of metabolic disorders
AU2002321764A1 (en) Genobix agonists and antagonists for use in the treatment of metabolic disorders
AU2002334250A1 (en) Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002321774A1 (en) Agonists and antagonists of contabix for use in the treatment of metabolic disorders
AU2002313581A1 (en) Lypergix agonists and antagonists for use in the treatment of metabolic disorders
AU2002313578A1 (en) Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
AU2002339689A1 (en) Dexar agonists and antagonists for use in the treatment of metabolic disorders
AU2002324299A1 (en) Genoxit agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) Glucoset agonists and antagonists for use in the treatment of metabolic disorders
AU2002313579A1 (en) Agonists and antagonists of famoset for use in the treatment of metabolic disorders